UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-41331 AN2 Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 82-0606654 (State or ...

Exhibit 99.1 AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline Epetraborole-treated patients demonstrated clinical improvements in QOL-B and a post-hoc analysis of MACrO2 with nominal statistical significance when evaluated as continuous measures First drug candidate with statistically favorable patient reported outcome (PRO)-based improvement in treatment-refractory Mycobacterium avium Complex (TR-MAC) po ...

AN2 Therapeutics (ANTX) , a clinical-stage company, leverages its boron chemistry platform to develop novel small molecule therapeutics to potentially treat various infectious diseases and cancer indications.The company is currently evaluating its lead clinical-stage candidate, epetraborole, a bacterial leucyl-tRNA synthetase inhibitor, for nontuberculous mycobacteria (NTM) lung disease and acute melioidosis in separate early-stage studies.In the past month, shares of AN2 Therapeutics plunged 66.3% after th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-41331 | --- | --- | |------------------------------------------------------------------------------------------------- ...

Exhibit 99.1 AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights Cash, cash equivalents, and investments of $104.5 million at June 30, 2024; cash runway anticipated to fund operations through 2027 Menlo Park, CA – August 13, 2024 – AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform today reported financial results for the q ...

AN2 Therapeutics (NASDAQ:ANTX) stock is taking a beating on Friday after the company provided an update on its EBO-301 Phase 2/3 study.AN2 Therapeutics notes that information comes from the Phase 2 study of epetraborole as an optimized background regimen (OBR) in treatment-refractory MAC lung disease. That includes it meeting its primary endpoint but failing to meet a key secondary endpoint.On top of that, the company notes that it stopped accepting new patients to the Phase 3 part of the study in February. ...

A downtrend has been apparent in AN2 Therapeutics, Inc. (ANTX) lately with too much selling pressure. The stock has declined 5.5% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicato ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-41331 | --- | --- | |------------------------------------------------------------------------------------------------ ...

Exhibit 99.1 AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights Plan to report Phase 2 topline results in August 2024 from ongoing Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) Phase 3 continues for 97 patients enrolled before the voluntary enrollment pause; lifting of the Phase 3 enrollment pause to be determined after review of unblinded Phase 2 data and discussions with the FDA Cash, cash equivalents, and in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-41331 AN2 Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-0606654 (State or other jurisdiction ...